Key Investor Signals
Raised $1M in pre-seed financing for multi-omic testing
Baobab Ventures, Kfund, Itnig, Masia and angel investors backed BASE4’s April 2026 pre-seed round to develop its blood-based, sex-specific biological modeling platform.
Secured transferred IP for blood-based tissue modeling
BASE4 was established through a Sant Pau technology-transfer agreement, with the underlying patent transferred to the company for its blood-based biological-age analysis.
Built on sex-specific research across 44 human tissues
Scientific co-founders Soria and Martínez-Pérez co-authored the 2020 Science study mapping sex differences in gene expression across 44 human tissue sources.
Team
Pol Cervera
CEO and Co-founder
- Co-founded Exheus, later Beyond You, and led operations and digital product work on its blood-based RNA analysis platform.
- Worked on business development and product operations for Larry AI, a nutrition agent for patients with cardiometabolic conditions.
- Has taught and mentored entrepreneurship at TecnoCampus since 2023, covering product validation and startup operations.
José Manuel Soria
CSO and Co-founder
- Has directed Sant Pau’s Genomics of Complex Diseases unit since 2006, leading research in personalized medicine and disease risk.
- Co-founded Exheus and served as CSO from 2020 to 2024, translating blood-based gene-expression research into a health-testing business.
- Completed postdoctoral research in haemostasis and thrombosis at Leiden University Hospital from 1995 to 1998.
Ángel Martínez-Pérez
CTO and Co-founder
- Has worked as a senior bioinformatics scientist at Sant Pau since 2007, building computational expertise in human genetic data.
- Co-authored the 2020 Science study mapping sex differences in gene expression across 44 human tissue sources.
- Co-developed lme4qtl, published in 2018, an R software package for genetic studies that model related individuals.
Product
BASE4 Biosciences analyzes blood-based gene activity and other molecular signals with AI models tailored by sex. It translates these measurements into tissue-level biological-age estimates and pathway insights for informational reproductive-health and preventive-health assessment.
Molecular blood analysis
A peripheral blood sample is processed to measure gene activity alongside other molecular signals. The platform combines transcriptomic and genetic information to characterize biological changes.
Sex-specific tissue models
AI models infer the functional state and biological age of multiple tissues using sex-specific patterns. The approach is designed to capture biological differences relevant to ovarian and broader organ health.
Organ and pathway interpretation
Results link organ-level signals with molecular pathways that may explain altered tissue function. Reproductive-health insights are informational and are intended for discussion with a qualified healthcare professional.
Market Overview
Women’s health testing serves patients and clinicians assessing reproductive function, hormonal changes and longer-term health. Fertility assessment and menopause-related care create recurring demand for interpretable biological information, alongside established laboratory and imaging services.
The market spans clinical laboratories, specialist practices and consumer testing services. Blood-based and home-sampling formats broaden access to reproductive-health information, while digital interpretation supports follow-up discussions. Molecular profiling also serves research buyers studying treatment response.
Global women’s health diagnostics revenue is estimated at $23.7B in 2026.
Global fertility-testing devices generated an estimated $2.5B in revenue in 2025.
Home-care settings represented 44.38% of global fertility-testing device revenue in 2025.
WHO’s 2025 fact sheet says 1 in 6 people of reproductive age experience infertility in their lifetime.
Comparable Outcomes
Modern Fertility
Offered at-home hormone tests that helped women understand fertility, ovarian reserve, and reproductive planning. Ro acquired Modern Fertility in May 2021 for a reported value of more than $225M, expanding its reproductive-health testing offering.
Genomic Health
Developed gene expression tests that predicted cancer recurrence and guided chemotherapy decisions. Exact Sciences announced its $2.8B acquisition of Genomic Health in July 2019 and completed the transaction in November 2019.
Interested in More Startups Like BASE4 Biosciences?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.